APELLIS PHARMACEUTICALS INC (APLS) Fundamental Analysis & Valuation

NASDAQ:APLS • US03753U1060

18.75 USD
+0.36 (+1.96%)
Last: Mar 13, 2026, 10:01 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This APLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to APLS. APLS was compared to 519 industry peers in the Biotechnology industry. APLS has only an average score on both its financial health and profitability. APLS is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

6

1. APLS Profitability Analysis

1.1 Basic Checks

  • APLS had positive earnings in the past year.
  • In the past year APLS had a positive cash flow from operations.
  • In the past 5 years APLS reported 4 times negative net income.
  • In the past 5 years APLS reported 4 times negative operating cash flow.
APLS Yearly Net Income VS EBIT VS OCF VS FCFAPLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • APLS's Return On Assets of 2.08% is amongst the best of the industry. APLS outperforms 88.44% of its industry peers.
  • The Return On Equity of APLS (6.05%) is better than 90.94% of its industry peers.
  • APLS has a Return On Invested Capital of 5.83%. This is amongst the best in the industry. APLS outperforms 91.14% of its industry peers.
Industry RankSector Rank
ROA 2.08%
ROE 6.05%
ROIC 5.83%
ROA(3y)-29.1%
ROA(5y)-51.55%
ROE(3y)-117.43%
ROE(5y)-222.36%
ROIC(3y)N/A
ROIC(5y)N/A
APLS Yearly ROA, ROE, ROICAPLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.23%, APLS belongs to the top of the industry, outperforming 88.44% of the companies in the same industry.
  • APLS has a better Operating Margin (5.52%) than 89.79% of its industry peers.
  • APLS has a better Gross Margin (89.81%) than 91.52% of its industry peers.
  • APLS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.52%
PM (TTM) 2.23%
GM 89.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1%
GM growth 5Y-0.05%
APLS Yearly Profit, Operating, Gross MarginsAPLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. APLS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), APLS is destroying value.
  • Compared to 1 year ago, APLS has more shares outstanding
  • Compared to 5 years ago, APLS has more shares outstanding
  • The debt/assets ratio for APLS has been reduced compared to a year ago.
APLS Yearly Shares OutstandingAPLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
APLS Yearly Total Debt VS Total AssetsAPLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • APLS has an Altman-Z score of -0.05. This is a bad value and indicates that APLS is not financially healthy and even has some risk of bankruptcy.
  • APLS has a Altman-Z score of -0.05. This is comparable to the rest of the industry: APLS outperforms 58.77% of its industry peers.
  • APLS has a debt to FCF ratio of 10.12. This is a negative value and a sign of low solvency as APLS would need 10.12 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 10.12, APLS belongs to the best of the industry, outperforming 90.94% of the companies in the same industry.
  • APLS has a Debt/Equity ratio of 0.98. This is a neutral value indicating APLS is somewhat dependend on debt financing.
  • APLS's Debt to Equity ratio of 0.98 is on the low side compared to the rest of the industry. APLS is outperformed by 74.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 10.12
Altman-Z -0.05
ROIC/WACC0.64
WACC9.05%
APLS Yearly LT Debt VS Equity VS FCFAPLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M

2.3 Liquidity

  • APLS has a Current Ratio of 3.14. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
  • APLS has a Current ratio of 3.14. This is in the lower half of the industry: APLS underperforms 63.78% of its industry peers.
  • APLS has a Quick Ratio of 2.70. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of APLS (2.70) is worse than 66.09% of its industry peers.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 2.7
APLS Yearly Current Assets VS Current LiabilitesAPLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. APLS Growth Analysis

3.1 Past

  • APLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 108.97%, which is quite impressive.
  • The Revenue has grown by 28.46% in the past year. This is a very strong growth!
  • The Revenue has been growing by 31.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)108.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.07%
Revenue 1Y (TTM)28.46%
Revenue growth 3Y137%
Revenue growth 5Y31.99%
Sales Q2Q%-5.94%

3.2 Future

  • Based on estimates for the next years, APLS will show a very strong growth in Earnings Per Share. The EPS will grow by 85.77% on average per year.
  • APLS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.87% yearly.
EPS Next Y-1013.25%
EPS Next 2Y-113.28%
EPS Next 3Y87.13%
EPS Next 5Y85.77%
Revenue Next Year-14.16%
Revenue Next 2Y0.63%
Revenue Next 3Y6.05%
Revenue Next 5Y8.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
APLS Yearly Revenue VS EstimatesAPLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
APLS Yearly EPS VS EstimatesAPLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

5

4. APLS Valuation Analysis

4.1 Price/Earnings Ratio

  • APLS is valuated quite expensively with a Price/Earnings ratio of 144.23.
  • APLS's Price/Earnings ratio is rather cheap when compared to the industry. APLS is cheaper than 88.44% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.71, APLS is valued quite expensively.
  • The Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 144.23
Fwd PE N/A
APLS Price Earnings VS Forward Price EarningsAPLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

  • 90.94% of the companies in the same industry are more expensive than APLS, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 93.06% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 53.25
EV/EBITDA 41.06
APLS Per share dataAPLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • The decent profitability rating of APLS may justify a higher PE ratio.
  • A more expensive valuation may be justified as APLS's earnings are expected to grow with 87.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-113.28%
EPS Next 3Y87.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. APLS Dividend Analysis

5.1 Amount

  • APLS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

APLS Fundamentals: All Metrics, Ratios and Statistics

APELLIS PHARMACEUTICALS INC

NASDAQ:APLS (3/13/2026, 10:01:05 AM)

18.75

+0.36 (+1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners98.77%
Inst Owner Change2.42%
Ins Owners4.02%
Ins Owner Change1.59%
Market Cap2.40B
Revenue(TTM)1.00B
Net Income(TTM)22.39M
Analysts78.62
Price Target34.83 (85.76%)
Short Float %23%
Short Ratio8.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.55%
Min EPS beat(2)-21.01%
Max EPS beat(2)38.1%
EPS beat(4)2
Avg EPS beat(4)-13.31%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-6.29%
EPS beat(12)6
Avg EPS beat(12)-5.73%
EPS beat(16)7
Avg EPS beat(16)-5.68%
Revenue beat(2)1
Avg Revenue beat(2)4.35%
Min Revenue beat(2)-1.86%
Max Revenue beat(2)10.55%
Revenue beat(4)1
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.96%
Revenue beat(12)7
Avg Revenue beat(12)8.54%
Revenue beat(16)9
Avg Revenue beat(16)6.28%
PT rev (1m)0%
PT rev (3m)-3.87%
EPS NQ rev (1m)22%
EPS NQ rev (3m)18.58%
EPS NY rev (1m)-3.3%
EPS NY rev (3m)-5.88%
Revenue NQ rev (1m)5.85%
Revenue NQ rev (3m)6.09%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-0.32%
Valuation
Industry RankSector Rank
PE 144.23
Fwd PE N/A
P/S 2.39
P/FCF 53.25
P/OCF 52.88
P/B 6.48
P/tB 6.48
EV/EBITDA 41.06
EPS(TTM)0.13
EY0.69%
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)0.35
FCFY1.88%
OCF(TTM)0.35
OCFY1.89%
SpS7.85
BVpS2.9
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.91
Profitability
Industry RankSector Rank
ROA 2.08%
ROE 6.05%
ROCE 7.37%
ROIC 5.83%
ROICexc 15.34%
ROICexgc 15.34%
OM 5.52%
PM (TTM) 2.23%
GM 89.81%
FCFM 4.48%
ROA(3y)-29.1%
ROA(5y)-51.55%
ROE(3y)-117.43%
ROE(5y)-222.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1%
GM growth 5Y-0.05%
F-Score7
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF 10.12
Debt/EBITDA 6.35
Cap/Depr 20.09%
Cap/Sales 0.03%
Interest Coverage 1.34
Cash Conversion 79.54%
Profit Quality 201.06%
Current Ratio 3.14
Quick Ratio 2.7
Altman-Z -0.05
F-Score7
WACC9.05%
ROIC/WACC0.64
Cap/Depr(3y)28.62%
Cap/Depr(5y)52.72%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.07%
EPS Next Y-1013.25%
EPS Next 2Y-113.28%
EPS Next 3Y87.13%
EPS Next 5Y85.77%
Revenue 1Y (TTM)28.46%
Revenue growth 3Y137%
Revenue growth 5Y31.99%
Sales Q2Q%-5.94%
Revenue Next Year-14.16%
Revenue Next 2Y0.63%
Revenue Next 3Y6.05%
Revenue Next 5Y8.87%
EBIT growth 1Y133.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-249.58%
EBIT Next 3Y34.89%
EBIT Next 5Y28.94%
FCF growth 1Y151%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y151.59%
OCF growth 3YN/A
OCF growth 5YN/A

APELLIS PHARMACEUTICALS INC / APLS FAQ

Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to APLS.


What is the valuation status of APELLIS PHARMACEUTICALS INC (APLS) stock?

ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.


What is the profitability of APLS stock?

APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for APLS stock?

The Earnings per Share (EPS) of APELLIS PHARMACEUTICALS INC (APLS) is expected to decline by -1013.25% in the next year.